Clinical practice guidelines for hepatocellular carcinoma surveillance for people at high risk in Australia

Published by Dena Zeraatkar on Sep 25, 2023

Disclaimer

Sponsors

The Australian Government Department of Health and Aged Care commissioned and funded Cancer Council Australia to undertake the current revision and update of this guideline.

Contact

Abstract

Language

en-au

PICOS

PICO 2.1

Population
People with limited projected life expectancy
Intervention
Surveillance for HCC
Comparator
No surveillance for HCC
Outcomes

PICO 2.1

Population
People with non-cirrhotic liver disease
Intervention
HCC surveillance programs
Comparator
No surveillance; Usual or standard care
Outcomes

PICO 2.1

Population
Aboriginal and Torres Strait Islander peoples
Intervention
HCC surveillance programs
Comparator
No surveillance; Usual or standard care
Outcomes

PICO 2.1

Population
Asian or Pacific-born people in Australia
Intervention
HCC surveillance programs
Comparator
No surveillance; Usual or standard care
Outcomes

PICO 2.1

Population
sub-Saharan African-born people in Australia
Intervention
HCC surveillance programs
Comparator
No surveillance; Usual or standard care
Outcomes

PICO 2.1

Population
Adults with cirrhotic liver disease undergoing HCC surveillance
Intervention
HCC surveillance with 6-monthly ultrasound + AFP
Comparator
HCC surveillance with 6-monthly ultrasound only
Outcomes

PICO 2.2

Population
People with cirrhosis who are willing and suitable to receive HCC treatment
Intervention
6-monthly surveillance for HCC
Comparator
No surveillance for HCC
Outcomes

PICO 2.2

Population
HCC patients with non-cirrhotic liver disease
Intervention
Previous HCC surveillance
Comparator
No previous surveillance
Outcomes

PICO 2.2

Population
Adults with chronic HBV undergoing HCC surveillance
Intervention
HCC surveillance with 6-monthly ultrasound + AFP
Comparator
HCC surveillance with 6-monthly ultrasound only
Outcomes

PICO 2.3

Population
People with HCV and F3 fibrosis (non-cirrhotic) who achieve a sustained virologic response to treatment
Intervention
Surveillance
Comparator
No surveillance
Outcomes

PICO 2.4

Population
People with direct acting antiviral treated cirrhotic chronic HCV
Intervention
HCC surveillance programs
Comparator
No surveillance; Usual or standard care
Outcomes

PICO 2.5

Population
HCC patients with cirrhosis who have been treated for HCV with direct acting antivirals
Intervention
Previous HCC surveillance
Comparator
No previous surveillance
Outcomes